Retention of oncogenicity by a Marek's disease virus mutant lacking six unique short region genes.
about
Growth hormone interacts with the Marek's disease virus SORF2 protein and is associated with disease resistance in chickenReconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant.Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV.Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5aRescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function.The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virusRetroviral insertional activation in a herpesvirus: transcriptional activation of US genes by an integrated long terminal repeat in a Marek's disease virus clone.A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation.Recombinant Marek's disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a marker gene within the context of the MDV genome.The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component.The glycoprotein D (US6) homolog is not essential for oncogenicity or horizontal transmission of Marek's disease virus.Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.Marek's disease virus latency-associated transcripts belong to a family of spliced RNAs that are antisense to the ICP4 homolog gene.The Leeuwenhoek Lecture, 1997. Marek's disease herpesvirus: oncogenesis and prevention.
P2860
Q30997074-C7CAEC0D-2C7C-4734-A530-9C139930491EQ33826716-37F8914D-08E6-4B02-97F8-F357AADFF8BAQ33851816-4CC10EC5-C613-48C1-B6DA-BBD0B7302C38Q33987363-A09ED45F-FF03-4E2D-A034-7AD229E3893FQ34068331-C2E5DF7B-F624-4FDD-A00D-25158AA2A81FQ35760645-F95FF544-F46D-4C37-B275-B55F14777EB4Q35859049-5689C17A-1494-44FD-8FF7-6A61CBFE7255Q36289021-1B497F0B-90FD-43B5-BBB8-02AE078582A9Q39549411-CFDCFB48-D6D0-4F78-9E5B-14A7EBCA7946Q39550148-7F1202C8-2B3B-46A3-ADD6-DBFD87BAF183Q39578082-E8D04819-48DA-492F-B33A-CD77945D830EQ39590202-A8E8D55F-637A-48D5-B1D2-82A36EAD96F9Q39878173-5E99BF14-4EFF-4F8F-855F-1E2C0476B543Q40845345-02871437-05E9-415C-B37C-35CD7EDB56EF
P2860
Retention of oncogenicity by a Marek's disease virus mutant lacking six unique short region genes.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Retention of oncogenicity by a ...... six unique short region genes.
@en
Retention of oncogenicity by a ...... six unique short region genes.
@nl
type
label
Retention of oncogenicity by a ...... six unique short region genes.
@en
Retention of oncogenicity by a ...... six unique short region genes.
@nl
prefLabel
Retention of oncogenicity by a ...... six unique short region genes.
@en
Retention of oncogenicity by a ...... six unique short region genes.
@nl
P2093
P2860
P1433
P1476
Retention of oncogenicity by a ...... six unique short region genes
@en
P2093
Anderson AS
Parcells MS
P2860
P304
P407
P577
1995-12-01T00:00:00Z